|
Aug 26
|
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
|
Jul 25
|
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
|
Jun 18
|
Cellectis (CLLS) Upgraded to Buy: Here's Why
|
|
Jun 18
|
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
|
|
Jun 12
|
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
|
|
May 7
|
AstraZeneca concludes equity investment in Cellectis
|
|
May 6
|
AstraZeneca ups stake in Cellectis in latest cell therapy bet
|
|
May 6
|
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
|
|
Apr 22
|
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
|
|
Jan 16
|
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
|
|
Dec 22
|
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
|
|
Dec 1
|
Monthly information on share capital and company voting rights
|
|
Jun 28
|
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
|
|
Apr 27
|
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
|
|
Apr 24
|
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
|